A real-world analysis of approximately 8,000 patients from the Cleveland Clinic found considerably less weight regain than clinical trial data would predict largely because many real-world patients transition to another weight-loss agent, restart semaglutide, or maintain structured lifestyle interventions after stopping
It requires subcutaneous injection and is often used alongside other diabetes treatments like insulin or sulfonylurea
People struggling with addiction behave differently
Further subgroup analysis revealed that, compared to diabetic populations, semaglutide had a more significant reduction in SBP ( 1.87, 95% CI 2.67 to 1.06, vs 5.02, 95% CI 6.10 to 3.94) and DBP ( 0.43, 95% CI 0.89 to 0.02, vs 1.96, 95% CI 3.12 to 0.80) in non-diabetic populations